Verrica Pharmaceuticals
VRCA
41 hedge funds and large institutions have $105M invested in Verrica Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 3 closing their positions.
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
8% more capital invested
Capital invested by funds: $97M → $105M (+$7.77M)
3% more funds holding
Funds holding: 40 → 41 (+1)
0.08% more ownership
Funds ownership: 3.43% → 3.51% (+0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.41M |
| 2 |
State Street
Boston,
Massachusetts
|
+$905K |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$585K |
| 4 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$334K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$242K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$2.53M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$559K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$58.2K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$47.5K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$33.4K |
VRCA Hedge Fund Activity: Q2 2019 in Review
41 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2019, worth a combined $105M — up 8% from $97M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VRCA positions and 3 closed out — a net gain of 1 holder — while 19 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $1.41M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $2.53M sold.
- 41 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2019, up from 40 in Q1 2019.
- Funds reported $105M of Verrica Pharmaceuticals stock for Q2 2019, up 8% quarter-over-quarter.
- 4 funds opened new Verrica Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of +1 holder.
- The largest Verrica Pharmaceuticals buyer in Q2 2019 was BlackRock, an estimated $1.41M added.
- The largest Verrica Pharmaceuticals seller in Q2 2019 was Gilder Gagnon Howe & Co, an estimated $2.53M sold.
Based on aggregated 13F filings for Q2 2019.